Every time you push past your comfort zone during exercise — sprinting, lifting heavy, climbing a steep hill — your muscles ramp up anaerobic glycolysis¹¹ anaerobic glycolysis
The metabolic pathway that breaks down glucose without oxygen, producing lactate and ATP rapidly during intense effort and flood the local environment with lactate²² lactate
Often called "lactic acid" in popular culture, though at physiological pH it exists almost entirely as the lactate anion. Far from being a waste product, lactate is a crucial fuel source for the heart, brain, and oxidative muscle fibers. Getting that lactate out of the producing muscle and into tissues that can burn it as fuel is the job of monocarboxylate transporter 1 (MCT1), encoded by the SLC16A1 gene on chromosome 1.

The A1470T variant (rs1049434) changes a single amino acid at position 490 of the MCT1 protein — aspartate to glutamate³³ aspartate to glutamate
Both are negatively charged amino acids, so this is a conservative substitution. However, the subtle structural difference is enough to alter transport kinetics measurably (p.Asp490Glu). This seemingly minor change has measurable effects on how efficiently your muscles shuttle lactate across cell membranes during high-intensity exercise.

The Mechanism

MCT1 sits in the sarcolemma⁴⁴ sarcolemma
The cell membrane of skeletal muscle fibers of skeletal muscle fibers, particularly in oxidative (type I) and intermediate (type IIa) fibers. It works as a symporter, moving one lactate molecule together with one proton (H+) across the membrane. This is essential for the "lactate shuttle"⁵⁵ "lactate shuttle"
A concept introduced by George Brooks: lactate produced by glycolytic fibers is transported via MCT1 into oxidative fibers and other tissues (heart, brain, liver) where it is used as fuel or converted back to glucose — the process by which lactate produced during intense effort is redistributed to tissues that oxidize it for energy.

The A allele at rs1049434 produces a transporter with higher Vmax⁶⁶ Vmax
Maximum velocity of the transport reaction — the rate of lactate movement when the transporter is fully saturated for lactate transport. The original functional characterization⁷⁷ functional characterization
Merezhinskaya N et al. Mutations in MCT1 cDNA in patients with symptomatic deficiency in lactate transport. Muscle Nerve, 2000 found that individuals homozygous for the A allele had lactate transport rates 60-65% higher than T allele carriers. The T allele produces a transporter with increased Km⁸⁸ Km
Michaelis constant — the substrate concentration at which the enzyme operates at half its maximum rate. A higher Km means lower affinity, requiring more substrate to achieve the same transport rate, meaning lower affinity for lactate and reduced transport capacity under physiological conditions.

The Evidence

The association between rs1049434 and exercise performance has been replicated across multiple independent cohorts and sport types:

A large multi-ethnic study⁹⁹ large multi-ethnic study
Guilherme JPL et al. The MCT1 gene Glu490Asp polymorphism (rs1049434) is associated with endurance athlete status, lower blood lactate accumulation and higher maximum oxygen uptake. Biol Sport, 2021 of 2,075 subjects (1,208 Brazilian, 867 European) found the T allele significantly overrepresented among endurance athletes compared to controls. In a subset of 66 Hungarian athletes, TT carriers accumulated less blood lactate after high-intensity effort, and 46 Russian athletes with the TT genotype had higher VO2max.

Fedotovskaya et al.¹⁰¹⁰ Fedotovskaya et al.
Fedotovskaya ON et al. A common polymorphism of the MCT1 gene and athletic performance. Int J Sports Physiol Perform, 2014 studied 323 Russian athletes and 467 controls, finding the A allele at 71.8% in endurance athletes versus 62.5% in controls (P < 0.0001). Among 79 rowers, T allele carriers had elevated post-exercise blood lactate concentrations.

In a repeated sprint study¹¹¹¹ repeated sprint study
Massidda M et al. Influence of the MCT1-T1470A polymorphism (rs1049434) on repeated sprint ability and blood lactate accumulation in elite football players. Eur J Appl Physiol, 2021 of 26 elite Italian football players, A allele carriers completed the 5th and 6th sprints in a 6 x 30m test approximately 0.37-0.40 seconds faster than TT carriers — a meaningful difference at the elite level.

A separate injury study¹²¹² injury study
Massidda M et al. Influence of the MCT1 rs1049434 on Indirect Muscle Disorders/Injuries in Elite Football Players. Sports Med Open, 2015 of 173 elite Italian football players over five seasons found that AA carriers had significantly higher muscle injury rates (1.57 per season) compared to TT carriers (0.09 per season, P = 0.04), suggesting the higher lactate transport activity may contribute to greater metabolic stress on muscle fibers.

Practical Implications

This variant influences how you should structure high-intensity training. If you carry two copies of the A allele (AA), your MCT1 transporter works at peak capacity — you clear lactate efficiently between sprints and can maintain power output across repeated efforts. However, this efficiency comes with a trade-off: higher lactate flux through the muscle membrane may increase metabolic stress and injury susceptibility.

If you carry two copies of the T allele (TT), your lactate clearance is reduced, meaning you may need longer recovery between high-intensity intervals. However, your muscles may compensate by developing greater oxidative capacity and fat oxidation, which could benefit longer-duration endurance events.

The heterozygous AT genotype, carried by roughly half the population, represents an intermediate transporter capacity that balances sprint recovery with metabolic resilience.

Interactions

MCT1 works in concert with other monocarboxylate transporters. MCT4 (SLC16A3) handles lactate export from glycolytic fast-twitch fibers, while MCT1 handles import into oxidative fibers. Variants in both genes may interact to determine overall lactate kinetics during exercise.

The ACTN3 R577X variant (rs1815739) also influences muscle fiber type composition and exercise phenotype. Individuals with both the MCT1 AA genotype and ACTN3 RR genotype may have a compounded advantage for repeated sprint and power activities, though this specific interaction has not been studied in controlled trials.

Coagulation factor XI (FXI) sits at a pivotal junction in the clotting cascade: it amplifies clot formation in tissues with high fibrinolytic activity — the mouth, nose, and urinary tract — where clots dissolve rapidly and need reinforcement. The F11 gene on chromosome 4q35.2 encodes FXI, and the c.291del frameshift (rs1057517151) removes a single guanine from a GGG triplet run, shifting the reading frame from codon 98 and creating a truncated, non-functional protein. The ClinVar classification is likely pathogenic¹¹ likely pathogenic
ClinVar VCV000371284.3, submitted by Counsyl clinical laboratory, 2016.

This variant exemplifies one of medicine's interesting genetic paradoxes: a loss-of-function mutation that simultaneously raises your bleeding risk and may lower your risk of stroke and venous thromboembolism — because factor XI sits at the intersection of hemostasis (necessary clotting after injury) and thrombosis (pathological clotting that causes heart attacks and strokes).

The Mechanism

FXI is activated by factor XIIa in the contact pathway and by thrombin in a positive-feedback loop. Once activated, FXIa cleaves and activates factor IX, which in turn activates the tenase complex and drives the clotting cascade toward fibrin clot formation²² fibrin clot formation
The c.291del frameshift at codon 98 introduces a premature stop, eliminating the protein's catalytic serine protease domain entirely; no functional FXIa is produced from the affected allele.

The reason FXI deficiency causes a peculiar, site-specific bleeding pattern — rather than global deficiency — is that clot initiation via the extrinsic (tissue factor) pathway proceeds normally. It is clot maintenance that suffers: in tissues rich in fibrinolytic activity (plasminogen activators), FXI-mediated amplification is needed to sustain the clot against dissolution. This is why bleeding in FXI deficiency clusters at fibrinolysis-rich sites³³ clusters at fibrinolysis-rich sites
Antifibrinolytic drugs like tranexamic acid correct this mechanism and are the primary surgical prophylaxis; PMID 27216469 — dental extractions, tonsillectomies, urologic procedures — rather than causing the spontaneous joint bleeds characteristic of hemophilia A and B.

The Evidence

Bleeding risk. A 2022 retrospective study of 198 patients undergoing 252 surgical and obstetric procedures⁴⁴ 198 patients undergoing 252 surgical and obstetric procedures
Handa et al. Thromb Res. 2022; PMID 36521104 found that 13% of procedures resulted in clinically significant bleeding. Personal bleeding history was the strongest predictor (OR 5.92, p=0.001); FXI level itself was a weaker predictor, with a threshold of 40 U/dL showing only 47% sensitivity. A 2016 expert review⁵⁵ 2016 expert review
Wheeler & Gailani. Expert Rev Hematol. 2016; PMID 27216469 quantified the difference between genotype classes: heterozygous carriers face an odds ratio of 2.6 for excessive bleeding; homozygotes face OR 13.0. For high-risk procedures (tooth extraction, tonsillectomy, urologic surgery), approximately 60% of severely deficient patients bleed without prophylaxis⁶⁶ 60% of severely deficient patients bleed without prophylaxis
Wheeler & Gailani 2016 versus far fewer at low-fibrinolysis sites.

A 2025 Italian cohort study of 93 FXI-deficient patients⁷⁷ 93 FXI-deficient patients
Santacroce et al. Int J Mol Sci. 2025; PMID 41009375 found that 88% were heterozygotes with mean FXI levels of 39 IU/dL (range 18–79). Critically, 30.8% of heterozygotes experienced hemorrhagic events — consistent with the known principle that there is no reliable linear correlation between FXI level and bleeding severity (Pearson r = −0.18). A patient at 60 U/dL may bleed after tonsillectomy; another at 25 U/dL may not.

Stroke and VTE protection. The clinical paradox: Salomon et al. Blood 2008⁸⁸ Salomon et al. Blood 2008
115 patients with severe FXI deficiency (activity <15 U/dL) followed in Israel; PMID 18268095 found only 1 ischemic stroke observed vs. 8.56 expected — an approximately 8-fold reduction. A 2022 observational study of 7,578 tested patients⁹⁹ 2022 observational study of 7,578 tested patients
Moser et al. Thromb Haemost. 2022; PMID 34555861 showed FXI deficiency associated with aHR 0.55 for cardiovascular events and aHR 0.45 for VTE (both nonsignificant trends toward protection due to small event numbers, but directionally consistent with the Israeli data). This cardioprotective property of FXI deficiency has driven major pharmaceutical interest in FXI inhibitors as next-generation anticoagulants.

Population context. Severe FXI deficiency affects approximately 1 in 1,000,000 people globally¹⁰¹⁰ 1 in 1,000,000 people globally
MedlinePlus Genetics 2024. In Ashkenazi Jewish populations¹¹¹¹ Ashkenazi Jewish populations
Founder effect — two mutations (Type II and Type III) account for ~96% of affected alleles; PMID 2052060 the disease frequency rises dramatically: 1 in 450 individuals, with a heterozygous carrier frequency of approximately 1 in 8. The c.291del variant (rs1057517151) is a distinct frameshift reported in ClinVar as likely pathogenic — not one of the classic Ashkenazi founder mutations, and population frequency data are not available in gnomAD, consistent with extreme rarity.

Practical Implications

The critical action for carriers of this variant is preoperative disclosure — especially before any procedure involving the mouth, throat, nose, or urinary tract. Antifibrinolytic therapy (tranexamic acid) is the mainstay of surgical prophylaxis for most procedures, targeting the fibrinolytic mechanism underlying site-specific bleeding. For severely deficient patients undergoing major surgery, FXI concentrate or fresh frozen plasma may be required.

Women with FXI deficiency warrant specific attention around childbirth: postpartum hemorrhage risk is elevated, and obstetric teams should be informed in advance. Neuraxial anesthesia appears safe — the Handa 2022 study found no epidural hematomas in 174 neuraxial procedures, including 5 patients with FXI <10 U/dL.

Because FXI deficiency appears protective against ischemic stroke and VTE, carriers should exercise caution before using anticoagulants, antiplatelet agents, or NSAIDs that compound bleeding risk without a clear clinical indication. Conversely, the FXI deficiency status should not prompt thromboprophylaxis — it is not a prothrombotic condition.

Interactions

Compound heterozygosity in F11 — carrying two different loss-of-function mutations on opposite chromosomes — produces a clinical picture equivalent to homozygosity: severe FXI deficiency with <15 U/dL activity. The c.291del variant could compound with any other pathogenic F11 allele (including the Ashkenazi Type II (rs121965063 / E117X) or Type III (rs121965064 / F283L) mutations) to produce severe deficiency in individuals who received one allele from each parent.

Acquired conditions that also impair hemostasis (thrombocytopenia, antiplatelet therapy, liver disease, von Willebrand disease) compound with FXI deficiency to increase bleeding risk beyond what either condition alone predicts. The reverse is also true: individuals with both FXI deficiency and a prothrombotic variant (Factor V Leiden rs6025, or prothrombin G20210A rs1799963) may have partially opposing effects — the FXI deficiency offering some bleeding tendency while the thrombophilic variant pushes toward clotting — producing unpredictable net clinical behavior that warrants specialist assessment.

Adiponectin is a fat-tissue hormone with a counterintuitive property: its levels fall as body fat increases, precisely when its metabolic protection is most needed. Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease¹¹ Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. The metabolic effects of adiponectin depend entirely on two transmembrane receptors: ADIPOR1, which is dominant in skeletal muscle, and ADIPOR2, which is dominant in the liver. rs1058322 is an intronic variant in ADIPOR2 — it does not change the receptor's amino acid sequence, but carriers of the T allele show measurably lower ADIPOR2 mRNA expression in circulating immune cells, suggesting the variant influences gene expression through altered splicing or regulatory context.

The Mechanism

When adiponectin binds ADIPOR2 in the liver, two downstream pathways activate: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master metabolic sensor that shifts cells toward catabolism, increasing fatty acid oxidation and glucose uptake while suppressing hepatic fat synthesis and gluconeogenesis and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that transcribes genes for hepatic fatty acid oxidation and lipid export; ADIPOR2 is its primary activator in liver. Together, these reduce hepatic fat accumulation, improve insulin sensitivity, lower LDL, and suppress inflammatory lipid species. The T allele at rs1058322 appears to reduce ADIPOR2 expression, leaving fewer functional receptor molecules at the hepatocyte membrane — the adiponectin signal arrives but finds fewer docking stations, blunting both AMPK and PPARα activation. The net result is a liver that is measurably less responsive to adiponectin's metabolic protection.

The Evidence

The primary evidence comes from the Finnish Diabetes Prevention Study (DPS)⁴⁴ Finnish Diabetes Prevention Study (DPS)
A randomized lifestyle intervention trial in Finland enrolling individuals with impaired glucose tolerance (IGT); 484 participants were genotyped for ADIPOR2 variants and followed for a median of 10.2 years for cardiovascular events. The rs1058322 T allele was dose-dependently associated with higher CVD risk: the additive model showed HR 1.601 (95% CI 1.021–2.509, p = 0.040) and the dominant model HR 1.711 (95% CI 1.114–2.627, p = 0.014). When rs1058322 was tested alongside three other ADIPOR2 variants in a joint multi-SNP model, it remained a significant independent predictor (p = 0.020), indicating unique risk information not redundant with other ADIPOR2 loci (r² = 0.094 with rs11061937).

The expression data that mechanistically links the variant to risk comes from the Genobin sub-study within the DPS analysis (n = 56)⁵⁵ Genobin sub-study within the DPS analysis (n = 56)
A Finnish metabolic cohort used to validate expression phenotypes discovered in the DPS genetic analysis; Siitonen et al. Cardiovasc Diabetol, 2011. Carriers of the T allele showed significantly lower ADIPOR2 mRNA levels in peripheral blood mononuclear cells compared with CC homozygotes (p = 0.029), providing a biological mechanism: T allele → reduced receptor expression → blunted adiponectin signaling → elevated cardiometabolic risk.

The broader biology is supported by receptor-disruption experiments: AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism⁶⁶ AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism
Bjursell M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007. Synthetic ADIPOR agonists that activate both receptors reduce insulin resistance and extend lifespan in obese diabetic mice⁷⁷ reduce insulin resistance and extend lifespan in obese diabetic mice
Okada-Iwabu et al. AdipoRon improves obesity-related metabolic disease. Nature, 2013, validating the pathway as therapeutically relevant and confirming that augmenting receptor signaling can meaningfully offset metabolic risk.

Practical Actions

The actionable targets for this variant are strategies that raise circulating adiponectin concentration — increasing the ligand supply to partially compensate for reduced receptor density — and that support hepatic fatty acid oxidation and AMPK activation independently. Omega-3 fatty acids (EPA and DHA) raise serum adiponectin in intervention studies and are the most directly relevant dietary lever. Replacing saturated fat with polyunsaturated sources raises adiponectin by 10–15% in dietary intervention trials. Given the CVD signal from the Finnish DPS, cardiometabolic monitoring is appropriate for T allele carriers, particularly those with additional risk factors such as impaired fasting glucose, elevated triglycerides, or a family history of cardiovascular disease.

Interactions

rs1058322 was co-analyzed with rs11061937, rs10848554, and rs16928751 in the Finnish DPS; all four SNPs showed nominal CVD associations and rs1058322 maintained independent significance alongside rs11061937 in the multi-SNP model. These variants tag distinct positions across the ADIPOR2 locus and may collectively describe a haplotype with compounded effects on receptor expression or function. Individuals carrying T alleles at rs1058322 alongside risk alleles at rs11061937 may have a more substantially reduced hepatic adiponectin response than either variant alone predicts. The interaction warrants a compound action (see harvesting notes below).

Aromatase — encoded by CYP19A1 on chromosome 15 — is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone) in peripheral tissues. Unlike the ovaries and testes, which produce estrogen in bulk, bone, fat, liver, brain, and breast tissue rely on local aromatase activity to maintain estrogen sufficiency around individual cells. rs1062033 sits approximately 12 kilobases upstream of the CYP19A1 translation start site in a regulatory region that controls which tissues express aromatase and in what amounts. This variant alters the binding of CEBPβ¹¹ CEBPβ
CCAAT/enhancer-binding protein beta, a transcription factor that regulates tissue-specific gene expression to the promoter, producing allele-specific differences in aromatase expression that downstream affect local estrogen concentrations — particularly in bone.

The Mechanism

The rs1062033 C>G change lies in an intronic regulatory region of CYP19A1 that acts as a tissue-specific promoter element. Electrophoretic mobility shift assays demonstrated that the C and G alleles bind the CEBPβ transcription factor with different affinities, and transient transfection experiments in osteoblastic cells showed allele-specific differences in luciferase reporter activity when a CEBPβ expression vector was co-introduced. Critically, differential allelic expression was confirmed directly in human bone tissue samples — not just in cell culture — making this one of the few CYP19A1 regulatory variants with direct in-tissue functional evidence rather than predicted regulatory effects alone.

The practical consequence flows through estrogen's effects on bone remodeling: estradiol suppresses osteoclast activity (bone breakdown) and supports osteoblast survival (bone formation). Women with alleles that sustain higher local aromatase activity in bone cells maintain greater estrogen-driven bone protection even as circulating ovarian estrogen declines after menopause. The interaction with vitamin D and calcium is indirect: estrogen upregulates calcium absorption in the gut (via calcium-binding protein calbindin-D9k²² calcium-binding protein calbindin-D9k
CALB1) and reduces urinary calcium loss — so allele-driven differences in aromatase activity propagate into effective calcium and vitamin D utilization in bone.

The Evidence

The foundational study by Riancho et al. 2009³³ Riancho et al. 2009
J Bone Miner Res — 1,163 postmenopausal women; rs1062033 as a true regulatory polymorphism with CEBPβ-binding evidence and allele-specific expression in human bone showed that opposing homozygotes (CC vs. GG) differed by 4.2% in whole-cohort BMD, a difference that expanded to 7.3% in women older than 67 — the age group with the greatest cumulative loss of ovarian estrogen support. This dose-response pattern across age is consistent with a lifetime accumulation of allele-driven differences in local bone estrogen signaling.

A Chinese Han case-control study Chen et al. 2024⁴⁴ Chen et al. 2024
Bladder cancer; 217 cases, 550 controls; OR=0.36 for G vs. C, FDR-p<0.001; rs1062033 correlated with CYP19A1 expression in whole blood independently confirmed that rs1062033 modifies CYP19A1 expression levels in blood, and found the G allele strongly protective against bladder cancer — a tissue where estrogen signaling is known to influence carcinogenesis risk.

The variant also modifies hormone circulating levels in response to environmental exposures. Kopp et al. 2016⁵⁵ Kopp et al. 2016
BMC Cancer — 687 cases/controls; rs1062033 associated with estrone sulphate levels (p=0.007) and interacted with alcohol to influence circulating hormone concentrations (p-interaction=0.03) demonstrated that the genotype influences baseline circulating estrone sulphate independently of hormone replacement therapy, and that the gene-environment interaction with alcohol is allele-specific.

Practical Actions

The primary clinical implication of this variant is in bone health for postmenopausal women. Carriers of two C alleles have lower aromatase-driven local estrogen in bone tissue, particularly relevant after menopause when peripheral aromatization becomes the dominant estrogen source. For these individuals, optimizing the cofactors that amplify bone-protective signaling — adequate vitamin D for calcium absorption, calcium intake distributed across meals for absorption efficiency, and weight-bearing activity to provide mechanical stimulus — becomes more important than for GG carriers, who retain higher local aromatase expression. Bone density monitoring starting from perimenopause is advisable to detect loss early when intervention is most effective.

Men also express aromatase in bone tissue, and testosterone therapy outcomes differ by rs1062033 genotype — indicating the variant's regulatory role in bone is not sex-exclusive, though the effect is smaller and evidence thinner in men.

Interactions

rs1062033 interacts epistatically with the IL-10 promoter variant rs1800896 in Alzheimer's disease risk — but only in women, with a synergy factor of 1.94 in the Epistasis Project (1,757 AD cases, 6,294 controls). The proposed mechanism involves local brain estrogen synthesis: aromatase is expressed in neurons and astrocytes, and locally produced estradiol modulates neuroinflammatory signaling via estrogen receptor beta. When aromatase activity is lower (CC genotype) AND IL-10 production is impaired (rs1800896 risk allele), the combined inflammatory environment in postmenopausal brain tissue may compound Alzheimer's risk beyond either variant alone. This interaction is not yet actionable as an independent clinical signal, but it illustrates the reach of aromatase regulation beyond bone.

rs700518 (also in CYP19A1, ~12 kb away) is the most studied bone-BMD variant in this gene and has a more robust evidence base for BMD effects in both sexes. Both variants modulate aromatase expression in bone but through distinct regulatory elements; their combined effect has not been formally characterized.

The SERPING1 gene encodes C1-inhibitor (C1-INH)¹¹ C1-inhibitor (C1-INH)
Serpin family G member 1 — a serine protease inhibitor that circulates in the blood and is the primary brake on the complement and contact activation pathways, the body's frontline inflammatory response systems. C1-INH keeps these systems from running uncontrolled. When C1-INH is absent or non-functional, the contact activation pathway generates bradykinin — a potent peptide that opens blood vessel walls and drives fluid into surrounding tissues. The result is hereditary angioedema (HAE): unpredictable, recurrent episodes of severe swelling affecting the skin, gut, and airway.

The c.856del variant removes a single cytosine nucleotide at position 856 of the SERPING1 coding sequence, causing a frameshift that alters every amino acid from position 286 onward and almost certainly triggers nonsense-mediated mRNA decay — destroying the transcript and producing no C1-INH protein from that allele. This is the molecular signature of HAE Type I, the most common form. HAE affects approximately 1 in 50,000 people globally²² 1 in 50,000 people globally
Fisch et al. 2025 systematic review; prevalence 0.13–1.6 per 100,000 across regions, with no significant difference between ancestries.

The Mechanism

C1-INH is the dominant inhibitor of factor XIIa and plasma kallikrein³³ factor XIIa and plasma kallikrein
the two key enzymes of the contact activation pathway that ultimately produce bradykinin from kininogen as well as complement proteases C1r and C1s. When one SERPING1 allele carries a frameshift, circulating C1-INH levels fall to approximately 30–50% of normal — insufficient to fully suppress kallikrein activity. Bradykinin surges drive episodes of submucosal and subcutaneous edema⁴⁴ submucosal and subcutaneous edema
Non-pitting swelling in the deep dermis and submucosa, not at the skin surface — which is why antihistamines and corticosteroids, which target mast-cell-driven superficial edema, are ineffective in HAE. Attacks commonly affect the face, hands, feet, genitalia, and gastrointestinal tract (abdominal pain mimicking a surgical emergency), and the larynx — where swelling can obstruct the airway within hours.

HAE follows autosomal dominant inheritance⁵⁵ autosomal dominant inheritance
One mutant allele is sufficient to cause disease — the remaining functional allele cannot compensate for the 50% reduction in C1-INH. Each child of an affected parent has a 50% chance of inheriting the mutation. Even first-degree relatives with no personal history of swelling should be tested. De novo mutations occur in approximately 20–25% of cases, so a negative family history does not rule out the diagnosis.

The Evidence

The mortality data from HAE are stark. A landmark study by Bork et al.⁶⁶ Bork et al.
Journal of Allergy and Clinical Immunology, 2012 — 728 patients across 182 families found that 70 of 214 deceased patients died from asphyxiation during laryngeal attacks. Among those who died from asphyxiation, 63 had never received a diagnosis of HAE — they lived on average 31 years shorter than HAE patients who died from other causes. The systematic review by Guan et al.⁷⁷ Guan et al.
Orphanet Journal of Rare Diseases, 2024 — 65 studies, 10,310 patients quantified the overall asphyxiation mortality risk at 8.6%, with a mean diagnostic delay of 3.9 to 26 years. This diagnostic gap is where most preventable deaths occur.

The mutation spectrum of SERPING1 is broad. A Spanish cohort study by López-Lera et al.⁸⁸ López-Lera et al.
Molecular Immunology, 2011 — 59 families identified 52 distinct mutations, of which 15 (29%) were frameshifts. Frameshift mutations virtually always abolish protein production entirely (Type I HAE), in contrast to some missense mutations that allow secretion of a non-functional protein (Type II HAE). The clinical phenotype across frameshift mutations is similar — the specific nucleotide deleted matters less than the consequence: absent C1-INH.

Modern therapies have transformed HAE management. The HELP trial⁹⁹ HELP trial
Riedl et al., Allergy, 2020 — lanadelumab subcutaneously every 2–4 weeks showed 85.7–100% of patients achieved a ≥50% attack reduction compared to 26.8% on placebo, with 37.9–48.1% becoming completely attack-free. The APeX-2 trial¹⁰¹⁰ APeX-2 trial
Zuraw et al., JACI, 2021 — berotralstat 150 mg daily showed an oral agent reduced attacks from 2.35 to 1.31 per month (P<0.001). For acute attacks, icatibant¹¹¹¹ icatibant
Cicardi et al., NEJM, 2010 — FAST-1/2 trials (a bradykinin B2 receptor antagonist) reduced time to symptom relief to 2.0–2.5 hours compared to 4.6–12.0 hours for control, making it a reliable on-demand treatment.

Practical Actions

For carriers of this mutation, the primary priority is an accurate diagnosis followed by access to on-demand acute treatment — carried at all times — and an individualized prophylaxis plan. Laryngeal attacks follow a predictable progression: a predyspnea phase averaging 3.7 hours, then a dyspnea phase averaging 41 minutes, then rapid deterioration. Treatment must begin in the predyspnea phase. First-degree relatives should be tested regardless of symptom history — asymptomatic carriers can develop their first severe attack at any age, and attacks are frequently triggered by surgery, dental procedures, stress, estrogen-containing contraceptives, or infection.

Estrogen-containing medications (oral contraceptives, hormone replacement therapy) can precipitate and worsen HAE attacks by reducing C1-INH levels further and increasing bradykinin production. Women with this mutation should specifically avoid estrogen-containing preparations and discuss progestogen-only or non-hormonal alternatives with their physician.

Interactions

HAE attacks can be triggered or worsened by ACE inhibitors — drugs used for blood pressure and heart failure — because ACE normally degrades bradykinin, and ACE inhibition allows bradykinin to accumulate. HAE patients receiving this mutation result should review all current medications with their treating allergist or immunologist, as several drug classes interact meaningfully with the bradykinin pathway.

Polycystic ovary syndrome affects 5–15% of women of reproductive age and carries a substantially elevated risk of cardiovascular and thrombotic complications. A 2018 genome-wide meta-analysis by Day et al. in PLoS Genetics¹¹ Day et al. in PLoS Genetics
10,074 PCOS cases and 103,164 controls of European ancestry, fixed-effect inverse-variance-weighted meta-analysis identified rs10739076 near the PLGRKT gene as one of three newly discovered PCOS susceptibility loci — reaching genome-wide significance (P<5×10⁻⁸). PLGRKT encodes the plasminogen receptor with a C-terminal lysine, a transmembrane protein that is central to the fibrinolytic system and, as emerging data show, to metabolic regulation in adipose tissue.

The Mechanism

PLGRKT (Plg-RKT)²² PLGRKT (Plg-RKT)
plasminogen receptor with C-terminal lysine; gene ID 55848, chromosome 9, complement strand is a structurally unique transmembrane receptor that tethers plasminogen to the surface of cells by exposing a C-terminal lysine residue. Plasminogen bound to Plg-RKT is co-localized with the urokinase receptor (uPAR), allowing efficient conversion to plasmin³³ plasmin
a broad-spectrum serine protease that degrades fibrin clots and extracellular matrix. This cell-surface plasmin generation is the final step of fibrinolysis — the process that dissolves blood clots after they form.

The rs10739076 variant lies approximately 2 kb downstream of PLGRKT's last exon in an intergenic region that likely contains regulatory elements influencing PLGRKT expression. The locus also neighbors the relaxin/insulin-like family genes INSL4, INSL6, RLN1, and RLN2, which are endocrine hormones with roles in reproductive function. The C risk allele at rs10739076 is the population-major allele globally (~65%), meaning most people — and most women with PCOS — carry at least one C allele.

Beyond fibrinolysis, Samad et al. 2022⁴⁴ Samad et al. 2022
using adipose tissue from bariatric surgery patients and high-fat-diet mice lacking PLGRKT showed that PLGRKT deficiency leads to increased adipose inflammation, insulin resistance, hepatic steatosis, and impaired PPARγ signaling — linking this plasminogen receptor to the metabolic dysregulation characteristic of PCOS.

The Evidence

Women with PCOS already have a well-documented prothrombotic state independent of genotype. Mannerås-Holm et al. 2011 (74 PCOS women, 31 controls)⁵⁵ Mannerås-Holm et al. 2011 (74 PCOS women, 31 controls)
Journal of Clinical Endocrinology & Metabolism found significantly elevated PAI-1 activity (the primary inhibitor of fibrinolysis) and fibrinogen in PCOS, with PAI-1 predicted by high insulin and low SHBG (R²=0.526, P<0.001). Burchall et al. 2016 (107 PCOS/67 controls)⁶⁶ Burchall et al. 2016 (107 PCOS/67 controls)
Seminars in Thrombosis and Hemostasis confirmed "impaired fibrinolysis in PCOS" with PAI-1 elevated at 4.80 vs 3.66 U/mL (p<0.01) independent of age and BMI, plus elevated plasminogen levels — a pattern consistent with an overloaded fibrinolytic system that can't keep up with clot formation.

The rs10739076 C allele adds a genetic layer to this baseline prothrombotic risk. The 2024 Indian cohort study by Dadachanji et al. (497 PCOS cases, 233 controls)⁷⁷ Dadachanji et al. (497 PCOS cases, 233 controls)
European Journal of Obstetrics & Gynaecology found that rs10739076 was associated with reduced fasting glucose and protective effects on insulin resistance, gonadotropin, and lipid levels in PCOS women — suggesting the variant modifies metabolic severity within PCOS rather than simply conferring susceptibility. The 2025 multi-ancestry GWAS by Zhao et al. in Nature Genetics⁸⁸ 2025 multi-ancestry GWAS by Zhao et al. in Nature Genetics
12,419 Chinese + 13,773 European PCOS cases; 94 independent loci identified confirmed substantial cross-ancestry genetic architecture for PCOS, validating the PLGRKT-adjacent locus as a robust PCOS susceptibility signal.

Epidemiologically, the thrombotic consequences are clear: PCOS women have approximately a 2-fold elevated risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) versus controls, with the risk rising further with combined oral contraceptive use (RR 2.14, 95% CI 1.41–3.24).

Practical Actions

For women carrying the C risk allele — particularly CC homozygotes — the combination of PCOS biology and genetic predisposition at the fibrinolytic locus warrants specific attention to thrombotic risk factors. Marine omega-3 fatty acids (EPA/DHA) have consistent evidence for improving metabolic dysfunction in PCOS: reducing triglycerides, decreasing insulin resistance (negative association with HOMA-IR, β=−0.089), and reducing inflammatory markers. A 2024 review of clinical trials found n-3 PUFAs demonstrate "hypotriglyceridemic, cardioprotective and anti-inflammatory effects" in PCOS, making them a well-supported adjunct to standard care.

PAI-1 levels — the direct marker of fibrinolytic impairment — should be monitored in CC homozygotes with confirmed or suspected PCOS, as elevated PAI-1 combined with genetic susceptibility at the PLGRKT locus creates compounding prothrombotic risk. Oral contraceptive selection is particularly relevant: combined oral contraceptives (COCs) independently increase VTE risk ~2-fold in PCOS, so progestin-only options or non-hormonal methods may be preferable in women with additional thrombotic risk factors.

Interactions

rs2479106 and rs7852296 (DENND1A): These PCOS susceptibility loci at chromosome 9q33.3 affect androgen biosynthesis in theca cells. Women carrying risk alleles at both DENND1A and PLGRKT loci may have compounding PCOS severity — elevated androgens driving the hormonal phenotype alongside impaired fibrinolysis driving thrombotic risk. No compound effect study has directly examined this combination.

rs13405728 (LHCGR): The LH/hCG receptor PCOS locus. Elevated LH in PCOS independently elevates thrombotic risk through platelet activation; combination of LHCGR and PLGRKT locus risk genotypes represents a plausible but unstudied compound thrombotic risk pathway.

Every woman is born with her entire lifetime supply of eggs already formed. These primordial follicle oocytes sit in meiotic arrest, sometimes for decades, under constant threat from DNA damage accumulating over time — from metabolic byproducts, environmental toxins, radiation, and the simple passage of years. The protein that decides which of these oocytes survive and which are eliminated is TAp63α, an isoform of the p53 family member TP63¹¹ TAp63α, an isoform of the p53 family member TP63
TAp63α (Tumor Protein p63, alpha isoform) is expressed at exceptionally high levels in primordial follicle oocytes and acts as the transcriptional master regulator of genome integrity in this cell type. rs10804920 is an intronic variant within the TP63 gene on chromosome 3. In a landmark genome-wide association study, the T allele at this variant was associated with significantly later age at natural menopause — a signal that reflects better lifetime preservation of the ovarian follicle pool.

The Mechanism

TAp63α patrols primordial oocytes for unresolved DNA damage. In its inactive state it exists as a closed, dimeric structure. When checkpoint kinases detect double-strand DNA breaks — either from meiotic recombination errors or environmental genotoxic damage — CHK2 phosphorylates TAp63α first (priming), and then CK1 provides a second, decisive phosphorylation that opens the protein into its active tetrameric form²² CHK2 phosphorylates TAp63α first (priming), and then CK1 provides a second, decisive phosphorylation that opens the protein into its active tetrameric form
This sequential two-kinase activation model was established by structural biology studies at Goethe University Frankfurt. The activated TAp63α tetramer then functions as a transcription factor, driving expression of pro-apoptotic genes Puma and Noxa³³ Puma and Noxa
PUMA (p53 upregulated modulator of apoptosis) and NOXA are BCL-2 family proteins that release BAX/BAK to execute the mitochondrial apoptosis program. The result: the oocyte eliminates itself before its damaged DNA can be passed to an embryo.

The rs10804920 variant is intronic, meaning it does not alter the TAp63α protein sequence directly. Instead, it likely acts as a regulatory variant affecting TAp63α expression levels or isoform balance in primordial follicle oocytes — the tissue where TP63 expression is concentrated. The T allele (associated with later menopause) may reflect fine-tuned checkpoint activity that better distinguishes reparable from irreparable damage, preserving more healthy oocytes over time. The exact regulatory mechanism at this locus remains to be characterized.

The Evidence

The primary evidence comes from a 2021 genome-wide association study published in Nature by Ruth, Day, and colleagues⁴⁴ 2021 genome-wide association study published in Nature by Ruth, Day, and colleagues
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393-397, 2021, analysing age at natural menopause in approximately 200,000 women of European ancestry with replication in additional cohorts. rs10804920-T was identified as a genome-wide significant locus (p = 7×10⁻¹⁹) with a beta of 0.076 years per T allele — meaning each copy of the T allele is associated with approximately 1 month of later menopause timing. Women carrying TT (two protective T alleles) would be expected to experience menopause approximately 2 months later than CC homozygotes at this locus alone, reflecting cumulative effects across a lifetime of oocyte quality control.

The biological plausibility of TP63 as an ovarian aging determinant is exceptionally strong. Bolcun-Filas et al. demonstrated in Science (2014) that ablating the checkpoint kinase CHK2 completely reverses female infertility caused by either meiotic defects or ionizing radiation⁵⁵ Bolcun-Filas et al. demonstrated in Science (2014) that ablating the checkpoint kinase CHK2 completely reverses female infertility caused by either meiotic defects or ionizing radiation
Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science 343:533-536, proving that the CHK2→p63 axis is the dominant pathway eliminating damaged oocytes. Kerr et al. (Mol Cell, 2012) further showed that γ-irradiated female mice lacking Puma (the TAp63 downstream target) retain their fertility and produce healthy offspring at the same rate as unirradiated controls⁶⁶ Kerr et al. (Mol Cell, 2012) further showed that γ-irradiated female mice lacking Puma (the TAp63 downstream target) retain their fertility and produce healthy offspring at the same rate as unirradiated controls
DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell 48:343-352, establishing TAp63→Puma/Noxa as the mechanistically proven link between DNA damage exposure and ovarian reserve depletion.

Practical Implications

Because TP63 checkpoint activity is central to how oocyte DNA damage translates into follicle loss, exposures that increase DNA damage burden in primordial oocytes are directly relevant to this locus: ionizing radiation (medical scans, occupational exposure), tobacco smoke, certain chemotherapy agents, and persistent organic pollutants are documented genotoxic stressors for the ovary. Reducing unnecessary exposure lowers the signal reaching the TP63 checkpoint, which translates to slower reserve depletion over the reproductive lifespan.

Two supplements have documented evidence for reducing oocyte DNA damage upstream of the checkpoint. CoQ10 (ubiquinol form) suppresses DNA damage and apoptosis in aged oocytes by restoring mitochondrial function and reducing reactive oxygen species⁷⁷ suppresses DNA damage and apoptosis in aged oocytes by restoring mitochondrial function and reducing reactive oxygen species
Zhang et al. 2019, Free Radical Biology and Medicine, and melatonin enhances DNA double-strand break repair (NHEJ pathway) in oocytes during prophase arrest, reducing the γ-H2AX damage signal and preserving spindle integrity⁸⁸ enhances DNA double-strand break repair (NHEJ pathway) in oocytes during prophase arrest, reducing the γ-H2AX damage signal and preserving spindle integrity
Leem et al. 2019, Journal of Pineal Research. Both act upstream of the TAp63 checkpoint — by reducing the quantity of DNA damage that triggers it, fewer oocytes reach the apoptotic threshold.

Interactions

CHK2 pathway variants (ATM, CHEK2): The CHK2→TAp63 axis that activates p63 is itself regulated by upstream DNA damage sensor kinases. Variants in ATM (rs1801516) or CHEK2 (rs17879961) that affect checkpoint kinase activity would modulate how efficiently DNA damage is transmitted to TAp63. Women carrying unfavorable genotypes at both a TP63 regulatory variant and an upstream kinase variant (ATM, CHK2) may have an amplified or attenuated response to genotoxic exposures compared to either variant alone — a compound action candidate warranting dedicated analysis when both loci are in the database.

rs116098458 (TP63 regulatory variant): Other intronic and regulatory variants within TP63 may influence TAp63α expression in primordial follicle oocytes differently from rs10804920. The combined effect of multiple TP63 regulatory variants on checkpoint stringency has not yet been characterised in the literature.

Two genes sit on chromosome 9q33-34, separated by roughly 10 kilobases of intergenic DNA: TRAF1, a signaling adapter that modulates NF-kB activation, and C5, the complement protein that bridges innate and adaptive immunity. The rs10818488 polymorphism lies exactly in this gap — a regulatory SNP¹¹ SNP
Single nucleotide polymorphism — a single-letter DNA difference that varies between people that is one of the most robust and well-replicated non-HLA risk loci for rheumatoid arthritis (RA) identified to date. The A allele, carried by approximately 42% of Europeans, confers measurably elevated RA risk and is associated with faster joint destruction in established disease.

The Mechanism

rs10818488 maps to the intergenic region approximately 10 kb from both the TRAF1 and C5 transcription start sites. It does not change any protein directly. Instead, it alters the local regulatory landscape: the A allele creates a binding site for EP300²² A allele creates a binding site for EP300
EP300 is a histone acetyltransferase that opens chromatin and activates transcription; binding at this locus appears to alter TRAF1 expression levels in immune cells, a histone acetyltransferase that remodels chromatin and activates transcription. Experimental evidence from monocytes confirms the functional direction: carriers of risk alleles at this locus express less TRAF1 protein³³ less TRAF1 protein
Paradoxically, reduced TRAF1 expression leads to more inflammation because TRAF1 normally sequesters LUBAC, the linear ubiquitin assembly complex; without sufficient TRAF1, LUBAC is released and drives stronger NF-kB activation upon stimulation and produce increased amounts of TNF and IL-6. TRAF1's role in NF-kB regulation is paradoxical: while it amplifies survival signaling through TNFR family members, it also suppresses excessive TLR/NLR responses by sequestering LUBAC. Lower TRAF1 expression tips this balance toward enhanced inflammatory cytokine output.

This creates a self-reinforcing loop in RA pathogenesis: reduced TRAF1 expression → amplified TNF production → further joint inflammation → progressive erosive disease. The A allele's association with radiographic damage progression reflects exactly this mechanism.

The Evidence

The TRAF1-C5 locus was first established as an RA risk locus by Plenge et al. in the New England Journal of Medicine⁴⁴ Plenge et al. in the New England Journal of Medicine
A landmark 2007 genome-wide association study with stepwise replication across Dutch, Swedish, and US cohorts (2007), with rs10818488 confirmed across 2,719 RA patients and 1,999 controls (OR 1.28, 95% CI 1.17–1.39, p = 1.40×10⁻⁸). The population-attributable risk — the fraction of RA cases attributable to this variant — was 6.1%, making it one of the most consequential non-HLA loci. A candidate gene study⁵⁵ candidate gene study
Using targeted genotyping of biologically plausible genes rather than genome-wide scanning replicated the finding across four independent sample sets: the A allele gave an OR of 1.26 overall, with AA homozygotes showing OR 2.06 (95% CI 1.42–2.98) compared with GG carriers.

A meta-analysis of 24 studies⁶⁶ meta-analysis of 24 studies
Pooling 22,682 RA cases and 23,493 controls confirmed the association in Europeans (OR 1.229, 95% CI 1.094–1.381, p=0.001) but not significantly in Asians, where the directional effect is reversed in some analyses — a genuine genetic heterogeneity reflecting different LD patterns at this locus across ancestries. An updated meta-analysis⁷⁷ updated meta-analysis
21 studies, 15,171 cases and 13,998 controls, with population-stratified analysis found the G allele is paradoxically protective in Europeans but a weak risk allele in Asians, consistent with the A allele's European-ancestry risk direction.

Beyond susceptibility, the A allele is associated with disease severity: carriers show greater radiographic joint damage progression over time (p=0.008). Association with higher disease activity scores has been replicated in Middle Eastern populations. The variant also extends to systemic lupus erythematosus, with an OR of 1.21 (95% CI 1.12–1.31, p=5.0×10⁻⁶) in Europeans in a separate meta-analysis⁸⁸ a separate meta-analysis.

Practical Actions

For AA homozygotes carrying two copies of the risk allele, the priority is early recognition of RA symptoms and baseline autoantibody testing — anti-CCP (ACPA) and rheumatoid factor — since the A allele's risk is predominantly expressed in seropositive, erosive RA. Joint stiffness lasting over 30 minutes in the morning, symmetric swelling of small hand joints, and unexplained fatigue are the key early warning signs. Because this locus also influences response to anti-TNF biologics (rs3761847, a nearby proxy SNP at the same locus, predicts anti-TNF outcomes), genotype information from this region may eventually guide biologic selection.

For the heterozygous AG genotype, the modestly elevated risk warrants awareness rather than aggressive clinical action, unless compounded by HLA-DRB1 shared epitope alleles or PTPN22 R620W carriage.

Interactions

rs10818488 and rs3761847 are the two most studied SNPs at the TRAF1-C5 locus, located approximately 10 kb apart in the same intergenic haplotype block. In most populations they are in high linkage disequilibrium and tag the same risk haplotype. The nearby rs3761847 G allele has been associated with poor response to anti-TNF therapy in RA, while rs10818488 A allele captures the overall susceptibility signal. Carrying risk alleles at both SNPs likely identifies the highest-risk individuals at this locus.

PTPN22 rs2476601 (R620W) is the strongest non-HLA non-TRAF1 RA susceptibility variant; combined carriage of PTPN22 A allele and TRAF1-C5 A allele substantially elevates RA risk beyond either alone through independent immune signaling pathways (T-cell signaling threshold versus NF-kB regulation). TNFAIP3 rs13207033, a protective NF-kB regulatory variant at the 6q23 locus, may partially offset TRAF1-C5 risk through independent A20-mediated NF-kB suppression.

Vitamin D from sunlight or supplements is biologically inert until the liver converts it into 25-hydroxyvitamin D (25(OH)D)¹¹ 25-hydroxyvitamin D (25(OH)D)
Also called calcidiol — the main circulating form of vitamin D, and the standard measure of your vitamin D status on a blood test. From here, the kidneys make the fully active hormone calcitriol. This first hydroxylation step is performed primarily by a cytochrome P450 enzyme called CYP2R1, encoded on chromosome 11p15.2. Without this enzyme working efficiently, neither sun exposure nor dietary vitamin D can adequately raise circulating 25(OH)D levels.

The rs10832310 variant is an intronic tag SNP located in the neighboring PDE3B gene but in high linkage disequilibrium with regulatory variants at the CYP2R1 locus. The G allele marks a haplotype associated with reduced CYP2R1 expression or activity, resulting in less efficient 25-hydroxylation of vitamin D3.

The Mechanism

CYP2R1 is a microsomal cytochrome P450 enzyme expressed primarily in the liver, where it catalyzes the addition of a hydroxyl group to carbon-25 of vitamin D3 (cholecalciferol), converting it to 25(OH)D3. Cheng et al. 2004²² Cheng et al. 2004
Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. PNAS, 2004 provided definitive evidence for this role by identifying a patient with an inherited homozygous L99P mutation in CYP2R1 who had very low circulating 25(OH)D despite normal sun exposure and dietary intake. The mutation abolished enzyme activity entirely.

The rs10832310 G allele does not alter the CYP2R1 protein sequence directly — it tags a haplotype block that likely includes regulatory variants affecting CYP2R1 transcription. Colocalization analysis in the Kämpe et al. 2019 GWAS³³ Kämpe et al. 2019 GWAS
Kämpe A et al. Genetic variation in GC and CYP2R1 affects 25-hydroxyvitamin D concentration and skeletal parameters: A genome-wide association study in 24-month-old Finnish children. PLoS Genetics, 2019 found a 97.3% posterior probability of a shared causal variant between the GWAS signal and CYP2R1 expression in thyroid tissue, strongly implicating altered gene expression as the mechanism.

The Evidence

The primary GWAS identifying rs10832310 was conducted in 761 healthy term-born Finnish children at 24 months of age, who participated in a randomized clinical trial comparing 10 μg versus 30 μg daily vitamin D3 supplementation from age 2 weeks. The GWAS signal reached p = 4.24 × 10⁻¹¹, genome-wide significance. The G allele was associated with a decrease of approximately 7.5 units in serum 25(OH)D — a clinically meaningful reduction for a pediatric population. Critically, the effect size was consistent regardless of whether children received standard-dose or high-dose vitamin D3, indicating that this locus reduces baseline conversion efficiency rather than modulating supplementation response directly.

Haplotypes associating with low 25(OH)D at this locus also showed strong negative associations with pQCT (peripheral quantitative computed tomography) bone parameters at the distal tibia, consistent with vertical pleiotropy⁴⁴ vertical pleiotropy
An effect where one variant influences multiple downstream traits through a single causal pathway — here, lower 25(OH)D leads to reduced calcium absorption and impaired bone mineralization mediated by vitamin D status.

The broader CYP2R1 locus has been replicated in multiple independent GWAS. The Wang et al. 2010 Lancet GWAS⁵⁵ Wang et al. 2010 Lancet GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010 of 33,996 Europeans confirmed the chromosome 11 CYP2R1 region as one of three genome-wide significant loci for 25(OH)D, alongside DHCR7 (chromosome 11q) and GC (chromosome 4). The MrOS Sweden cohort⁶⁶ MrOS Sweden cohort
Björk A et al. Haplotypes in the CYP2R1 gene are associated with levels of 25(OH)D and bone mineral density, but not with other markers of bone metabolism. PLoS One, 2019 found 4.6–18.5% differences in mean 25(OH)D between CYP2R1 genotypes in a large adult cohort, with corresponding effects on femoral neck bone mineral density.

Beyond skeletal health, the CYP2R1 locus has been linked to type 1 diabetes risk⁷⁷ type 1 diabetes risk
Ramos-Lopez E et al. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev, 2007, multiple sclerosis susceptibility, and immune function — likely mediated through the immunomodulatory effects of calcitriol on regulatory T cells and antigen-presenting cells.

Practical Implications

The G allele at rs10832310 reduces the liver's ability to convert vitamin D3 into its circulating form, 25(OH)D. This means that sun exposure and dietary vitamin D are converted less efficiently. Supplementing with vitamin D3 (cholecalciferol) bypasses none of this step — it must still be hydroxylated by CYP2R1 — so GG carriers may need higher doses than standard recommendations to achieve the same circulating 25(OH)D levels. Monitoring via blood testing becomes more important to confirm that supplementation is achieving adequate levels rather than assuming a standard dose is sufficient.

The G allele is relatively common (approximately 37% globally, 43% in Europeans), making this a frequently relevant consideration. The effect is additive, so GG homozygotes experience roughly double the impact of CG heterozygotes.

Interactions

The CYP2R1 locus interacts with three other major vitamin D pathway variants. DHCR7 (rs12785878) controls how much substrate (7-dehydrocholesterol) reaches the skin synthesis pathway. GC/DBP (rs2282679) determines how efficiently 25(OH)D is transported in the blood. VDR (rs2228570, rs1544410) determines receptor sensitivity to active calcitriol. Wang et al. 2010 found that individuals in the highest-risk quartile across all three confirmed loci had 2.47 times the odds of vitamin D insufficiency compared to the lowest-risk quartile. Users carrying G alleles at both rs10832310 and other vitamin D pathway variants face compounding impairments across synthesis, transport, and receptor sensitivity.

When your HDL particles finish their journey through the bloodstream collecting excess cholesterol from tissues, they need somewhere to deliver it. That final destination is the liver, and the molecule that accepts the delivery is SR-BI¹¹ SR-BI
Scavenger Receptor class B type I — a cell-surface receptor that extracts cholesterol esters directly from HDL into hepatocytes, the critical last step of reverse cholesterol transport. The SCARB1 gene encodes SR-BI, and rs10846744 — an intronic variant — influences how well this receptor functions. Carriers of the C allele show measurably higher rates of subclinical atherosclerosis and coronary heart disease, even in the presence of normal or elevated HDL cholesterol levels.

The Mechanism

rs10846744 lies within an intron of SCARB1 on chromosome 12 (GRCh38: 12:124,827,879). As a non-coding variant, it does not change the SR-BI amino acid sequence, but it likely affects gene expression, mRNA splicing efficiency, or protein levels — collectively altering the rate at which HDL cholesterol can be cleared from circulation into the liver. When SR-BI function is compromised, HDL particles accumulate in the bloodstream. This creates the HDL paradox²² HDL paradox
Normally, higher HDL is protective. But if HDL is high because the receptor that removes it isn't working well, the cholesterol isn't actually being delivered to the liver for excretion — it's stuck in transit: an elevated HDL reading accompanied by impaired reverse cholesterol transport and, paradoxically, increased cardiovascular risk.

The Evidence

The strongest evidence comes from a MESA cohort analysis³³ MESA cohort analysis
Manichaikul et al. Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. ATVB, 2012 of 7,936 participants from four ethnic groups. The rs10846744 variant showed strong association with carotid intima-media thickness (cIMT) across all ethnicities (P=1.04×10⁻⁴), a validated marker of early atherosclerosis. In males specifically, the variant was significantly associated with incident cardiovascular disease events (P=0.01), with replication support in the Myocardial Infarction Genetics Consortium.

A subsequent multi-cohort study⁴⁴ multi-cohort study
Manichaikul et al. Lp-PLA2, SCARB1 rs10846744 variant, and cardiovascular disease. PLoS One, 2018 using CARDIoGRAMplusC4D data (hundreds of thousands of participants) confirmed that the C allele associates with coronary artery disease (OR 1.05, 95% CI 1.02–1.07, P=1.4×10⁻⁴). The same study found associations with Lp-PLA2 activity, LDL particle number, and DHA levels in MESA participants.

A Chinese Han cohort study⁵⁵ Chinese Han cohort study
Zeng et al. Influence of SCARB1 gene SNPs on serum lipid levels and susceptibility to coronary heart disease and cerebral infarction in a Chinese population. Gene, 2017 of 909 participants found the C allele significantly elevated CHD risk (OR 1.416, 95% CI 1.128–1.778, P=0.006). Notably, CC and CG carriers had higher HDL-cholesterol than GG carriers — illustrating the HDL paradox characteristic of SR-BI dysfunction.

Practical Actions

For C allele carriers, the impaired SR-BI function means the focus should shift from simply raising HDL cholesterol to optimizing HDL functionality and facilitating cholesterol clearance through alternative pathways. Omega-3 fatty acids (EPA and DHA) support HDL particle quality and enhance reverse cholesterol transport efficiency. Monitoring HDL function — not just HDL-C level — and tracking inflammatory markers such as Lp-PLA2 gives a more accurate cardiovascular risk picture than a standard lipid panel alone.

Interactions

rs10846744 is in the same gene as rs4238001 (an exonic SCARB1 variant), rs2278986 (another SCARB1 intronic SNP), and rs5888 (a synonymous coding variant). Combined analysis of multiple SCARB1 variants may capture more variance in SR-BI activity than any single SNP alone. SCARB1 also interacts with the APOE pathway (rs429358, rs7412): both genes govern how efficiently cholesterol is cleared from the bloodstream, so carriers of risk alleles in both genes may face compounded dysfunction in reverse cholesterol transport.